Skip to content

US · ATYR · BIOTECHNOLOGY

aTyr Pharma, Inc. (ATYR) intrinsic value and stock valuation

$3.82as of 2026-11-21 · Mkt cap 50.14M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

aTyr Pharma, Inc. DCF and intrinsic value

InvestorsCraft values ATYR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATYR’s statements →

aTyr Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 atyrpharma.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$190K-55.1% 5y CAGRd
20122025
Net income
-$-74.12M
20122025
Free cash flow
-$-62.06M
20122025
Total equity
$67.3M+16.4% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$190K$230K$350K$10.4M$0.00
Operating income-$-77.63M-$-67.91M-$-54.92M-$-46.4M-$-34.02M
Net income-$-74.12M-$-64.02M-$-50.39M-$-45.34M-$-33.77M
EPSd-$-797.07K-$-862.11K-$-939.94K-$-1.6M-$-1.77M
Operating cash flow-$-61.99M-$-69.12M-$-33.22M-$-41.89M-$-33.08M
Capital expenditure-$-80K-$-70K-$-4.21M-$-1.64M-$-190K
Free cash flow-$-62.06M-$-69.18M-$-37.44M-$-43.53M-$-33.27M
Total assets$94.2M$96.8M$120.7M$95.8M$115.5M
Total debt$12M$13.3M$15.1M$11.5M$1.38M
Net debt$1.29M$2.23M-$-7.45M$1.55M-$-960K
Total equity$67.3M$69.8M$90.5M$71.3M$109.1M
Cash and short-term investments$78.7M$72.1M$98.2M$66.2M$107.9M
Income statement
20252024202320222021
Revenue$190K$230K$350K$10.4M$0.00
Cost of revenue$1.55M$0.00$0.00$1.7M$1.3M
Gross profit-$-1.36M$230K$350K$8.69M-$-1.3M
Research and development expenses$60.2M$54.4M$42.3M$42.8M$23.3M
Selling, general and administrative expenses$17.6M$13.8M$13M$12.3M$10.8M
Other expenses-$-1.55M$0.00$0.00$0.00-$-1.3M
Operating expenses$76.3M$68.2M$55.3M$55.1M$32.7M
Cost and expenses$77.8M$68.2M$55.3M$56.8M$34M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.55M$1.54M$2.74M$1.7M$1.3M
Ebitda-$-72.56M-$-62.48M-$-47.66M-$-43.65M-$-32.47M
Operating income-$-77.63M-$-67.91M-$-54.92M-$-46.4M-$-34.02M
Total other income/expenses, net$3.51M$3.89M$4.52M$1.06M$240K
Income before tax-$-74.12M-$-64.02M-$-50.4M-$-45.34M-$-33.78M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-74.12M-$-64.02M-$-50.39M-$-45.34M-$-33.77M
Weighted average shares outstanding$93M$74.3M$53.6M$28.4M$19.1M
Weighted average diluted shares outstanding$93M$74.3M$53.6M$28.4M$19.1M
Balance sheet
20252024202320222021
Cash and short-term investments$78.7M$72.1M$98.2M$66.2M$107.9M
Net receivables$870K$1.74M$2.44M$11.8M$430K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$80.2M$82M$103M$80.9M$113.6M
Property, plant and equipment, net$10.4M$11.9M$14.1M$11.6M$1.81M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$2.23M$0.00$0.00$0.00$0.00
Total non-current assets$13.9M$14.9M$17.7M$14.9M$1.97M
Total assets$94.2M$96.8M$120.7M$95.8M$115.5M
Accounts payable$3.89M$4.32M$3.53M$3.11M$1.03M
Short-term debt$1.47M$1.25M$1.33M$890K$980K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$15.2M$15M$16.4M$13.9M$6.01M
Long-term debt$10.6M$12M$13.8M$10.6M$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.7M$12M$13.8M$10.6M$400K
Capital lease obligations$10.6M$13.3M$15.1M$11.5M$1.38M
Total liabilities$26.9M$27M$30.2M$24.5M$6.41M
Common stock$100K$80K$60K$30K$30K
Retained earnings-$-606.16M-$-532.05M-$-468.02M-$-417.63M-$-372.3M
Accumulated other comprehensive income (loss)-$-10K-$-40K-$-70K-$-430K-$-260K
Total equity$67.3M$69.8M$90.5M$71.3M$109.1M
Total investments$70.2M$61.1M$75.6M$56.2M$105.6M
Total debt$12M$13.3M$15.1M$11.5M$1.38M
Net debt$1.29M$2.23M-$-7.45M$1.55M-$-960K
Cash flow statement
20252024202320222021
Net income-$-74.12M-$-64.02M-$-50.39M-$-45.34M-$-33.77M
Depreciation and amortization$1.55M$1.54M$2.74M$1.7M$1.3M
Stock-based compensation$5M$2.99M$2.6M$2.15M$1.61M
Change in working capital$7.45M-$-6.92M$15M-$-830K-$-2.59M
Accounts receivable$860K$400K$9.05M-$-11.92M$1.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-30K-$-1.34M$3.26M$0.00$50K
Net cash provided by operating activities-$-61.99M-$-69.12M-$-33.22M-$-41.89M-$-33.08M
Investments in property, plant and equipment-$-80K-$-70K-$-4.21M-$-1.64M-$-190K
Acquisitions, net$10K$10K$0.00$0.00$50K
Net cash used for investing activities-$-5.05M$17.2M-$-20.13M$47.2M-$-91.57M
Common stock issued$66.4M$40.3M$66.5M$5.47M$110M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$66M$39.9M$66.2M$5.45M$110M
Net change in cash-$-1.03M-$-12.02M$12.9M$10.8M-$-14.62M
Cash at end of period$13M$14M$26M$13.2M$2.34M
Operating cash flow-$-61.99M-$-69.12M-$-33.22M-$-41.89M-$-33.08M
Capital expenditure-$-80K-$-70K-$-4.21M-$-1.64M-$-190K
Free cash flow-$-62.06M-$-69.18M-$-37.44M-$-43.53M-$-33.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About aTyr Pharma, Inc.

        aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

        CEO
        Sanjay S. Shukla
        Employees
        58
        Beta
        0.52

        Explore

        Frequently asked questions

        What is the intrinsic value of aTyr Pharma, Inc. (ATYR)?

        aTyr Pharma, Inc. (ATYR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATYR undervalued?

        ATYR trades at a price of $3.82 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.